Navigation Links
Randomized Clinical Trial of OrbusNeich's Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
Date:10/11/2010

HONG KONG, Oct. 11 /PRNewswire/ -- OrbusNeich today reported the completion of patient enrollment in a randomized clinical study of its Genous Bio-engineered R stent at 11 sites in China.

The primary objective of the 180 patient, controlled study is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor® Sprint stent in patients with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac Event (MACE) rates between the two groups at 12 months after implantation and 270 day angiographic Late Loss (LL). Patients enrolled in the study were split evenly between the control and test arms.

"Based on its unique design and healing technology, we believe that Genous has the potential to give physicians an additional option for treating patients," said Prof. Lu Shuzheng from Anzhen Hospital, principal investigator of the trial. "We are excited to complete enrollment in this study, which may bring further clinical support for the technology's use in China."

David Chien, vice chairman of OrbusNeich, added, "This first clinical study of Genous in China is significant in the full development of the technology. We look forward to seeing additional clinical support for the use of Genous in challenging cases, such as diabetic patients and those who cannot tolerate a year of dual antiplatelet therapy."

Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, in-stent thrombosis, MACE rates at 30, 60, 90, 180 and 270 days, as well as clinically driven Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR) and Target Lesion Failure (TLF) rates at 30, 60, 90, 180, 270 and 360 days.  

About Genous

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as other stents and balloons marketed under the names of Blazer™, R stent, Scoreflex™, Sapphire™, and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
2. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
3. CorMatrix Receives FDA IDE Approval to Begin Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM™ for Pericardial Closure
4. Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
5. ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
6. Ophthotech Enrolls Its First Patient in a Randomized, Controlled Phase II Study of E10030 in Macular Degeneration
7. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
10. West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial
11. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Australia Glaucoma Surgery Devices ... new report, "Australia Glaucoma Surgery Devices Market Outlook ... Australia Glaucoma Surgery Devices market. The report provides ... units) and average prices (USD) within market segement ... provides company shares and distribution shares data for ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... to grow in 2017-2023. Various reasons for growth of ... population, higher incidences of chronic diseases, high recovery cost ... aid services. Medical lifting sling refers to an ... limited mobility. These slings connect to the lift and ...
(Date:12/8/2016)... Dec. 8, 2016  Eli Lilly and Company (NYSE: ... its phase 3 EXPEDITION3 trial at the 9 th ... previously disclosed, solanezumab did not meet the primary endpoint ... initiated in people with mild dementia due to Alzheimer,s ... for solanezumab for the treatment of mild dementia due ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... , ... David J. Dykeman , Ginger Pigott , and ... at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg ... global Life Sciences & Medical Technology Group have been featured speakers at every DeviceTalks ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to ... convenient service for Texas, they are expanding their presence in Dallas. One of the ... that will bring new jobs to the Dallas and Forth Worth market. STAT takes ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... from offices headquartered in Hamilton County, is embarking on a charity drive with ... in finding new homes for orphaned or neglected senior dogs in the Cincinnati ...
Breaking Medicine News(10 mins):